Further development is required to speed commercialisation. Phase 1/2 clinical trials for influenza along with a number of pre-clinical studies for influenza and TB. The clinical trial will demonstrate safety and initial immunisation effectiveness in humans. The pre-clinical work will help refine further the ideal doses to use and the vaccination schedules for both influenza and TB.
In parallel with this, development will be continued for TB, and exploration of other uses for the technology will be made.
To enable this, we are seeking an investment of £4m – £5m.
We anticipate results within 18 months.